Molecular profiling of Parkinson's disease

Recruiting

Conditions: Parkinson's
10028037

Registration Number: NL-OMON39947

Lead Sponsor: eids Universitair Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 100

Inclusion Criteria

For all participants a minimum age of 18 years is required.
All patients with Parkinson's Disease (PD) must fulfill the United Kingdom Parkinson's Disease Society Brain Bank criteria for idiopathic PD. Patients with Dementia with Lewy Bodies (DLB) must fulfill the McKeith DLB criteria and all patients must be diagnosed with PD or DLB by a movement disorder specialist.
All participants must be able to give informed consent.
Buffy coats of controls are included if they have no diseases of the central nervous system or conditions associated with the immune system.

Exclusion Criteria

Participants should have no inflammatory diseases.
Participants are excluded when anti-inflammatory drugs (NSAIDs, corticosteroids), immunosuppressive medication or anti-oxidants (Vitamin C) are used.
Participants are excluded when having an infectious disease at the time of the measurements.
Participants who currently smoke are excluded.
Patients who underwent stereotactic surgery are excluded.

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main parameters of this study are the redox responses to pro-oxidant<br /><br>challenge tests and bioenergetics functions such as mitochondrial respiration<br /><br>and glycolytic activity. All patient groups will be characterized on<br /><br>environmental exposures (smoking, insecticides, herbicides). For redox<br /><br>susceptibility profiling, 20 ml blood will be drawn via venapuncture and a skin<br /><br>biopsy will be performed. Differences in redox response to toxin challenge will<br /><br>be determined in peripheral blood cells and induced pluripotent stem cells by<br /><br>differential labelling of reduced and oxidized cysteines residues with<br /><br>maleimide technology followed by Fluorescence Assisted Cell Sorting (FACS)<br /><br>analysis.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Clinical assessments will be used to assess the progression of the core<br /><br>features of PD, which is necessary to allocate patients to one of the<br /><br>subgroups. The patients with DLB will be assessed clinically to be able to<br /><br>compare the clinical function of PD and DLB patients.</p><br>